PhRMA Statement on Time Magazine Article

WASHINGTON, D.C. (February 21, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement:

“Today’s Time Magazine article focuses exclusively on costs, overlooking the tremendous value that innovative medicines deliver to patients and the health care system for only a small fraction of overall health spending. Across the spectrum of diseases, medications have significantly improved quality and length of life.

Washington State Research Institutions Have Conducted More Than 3,600 Clinical Trials of New Medicines Since 1999

 WASHINGTON, D.C. (January 29, 2013) –Working in collaboration with university medical schools, science centers, local hospitals and clinical research centers, America’s biopharmaceutical companies have conducted 3,664 clinical trials of new medicines in Washington over the last 13 years, a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA) shows.

Robust Biopharmaceutical Pipeline Offers New Hope for Patients

Washington, D.C. (January 17, 2013) —The biopharmaceutical pipeline is innovative and robust, with a high proportion of potential first-in-class medicines and therapies targeting diseases with limited treatment options, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).  

Medicines in Development: Older Americans

Innovation in the Biopharmaceutical Pipeline

Research in Your Backyard: Developing Cures, Creating Jobs - Pharmaceutical Clinical Trials in Wisconsin

Research in West Virginia

Research in Washington

Research in Virginia

Research in Oregon

Pages

Subscribe to RSS - Innovation